Art. -Nr.: HY-120602

WWL229

Kundenbewertung

Based on 1 Customer Validation

WWL229 is a selective inhibitor of carboxylesterase 3 (CES3) with an IC₅₀ 1.94 μM. WWL229 attenuates LPS (HY-D1056)-induced pro-inflammatory cytokine mRNA levels, inhibits lipolysis and adipose thermogenesis, impairs mitochondrial function, and promotes lipid storage. WWL229 can be used for the research of obesity, insulin resistance, type 2 diabetes, and lung inflammation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.49%
CAS. Nr.: 1338575-28-2
Formel: C₁₆H₂₂N₂O₅
Molecular Weight:322.36

Speicherung:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

WWL229 Chemical Structure

CAS. Nr.: 1338575-28-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[2]^[1]

CES3

1.94 μM (IC₅₀)

IL-6

Alle Carboxylesterase (CES) Isoform-spezifische Produkte anzeigen :

Alle PPAR Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

In Vitro

WWL229 (1 μM; 15 min) inhibits ~70% of CES1 activity in intact THP-1 monocytes^[1].
WWL229 attenuates LPS-induced IL-6 and TNFα mRNA levels in THP-1 macrophages, both with and without exogenous 2-AG^[1].
WWL229 (10-100 μM; 1 h) dose-dependently attenuates Isoproterenol (ISO) (HY-B0468)-induced lipolysis in differentiated 3T3-L1 and BAC adipocytes^[2].
WWL229 (10 μM; 1 h) attenuates ISO-induced upregulation of β-oxidation genes in BAC cells, and reduces basal, proton leak, and maximal mitochondrial respiration in both 3T3-L1 and BAC adipocytes^[2].
WWL229 (10 μM) downregulates thermogenic gene and protein expression in ISO-treated BAC cells, and inhibits PPAR transcriptional activity in both basal and ISO-stimulated conditions^[2].
WWL229 (0.1-100 μM; 30 min) potently and selectively inhibits Ces1d activity in WT C57BL/6 wild-type mouse lung membranes^[3].
WWL229 (30 μM; 1 h) has no effect on TxB₂ or PGE₂ levels or related gene expression in PMA-differentiated human THP-1 macrophages treated with LPS^[4].
WWL229 (10 μM; 45 min) selectively inhibits Ces3 activity in adipocyte proteomes, with no inhibitory effect on Ces1f, ABHD6, or other serine hydrolases detected by ABPP-MudPIT^[5].
WWL229 (5 mM; 30 min) significantly reduces ER-EM activity in Wistar rat liver ER fraction, demonstrating that the Ces1d lipolysis site is crucial for ER-EM recognition of hydrophobic aglycone substrates^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[2]

Cell Line:

Differentiated 3T3-L1 and BAC adipocytes
Concentration:

10; 100 μM
Incubation Time:

1 h
Result:

Had the blocking effect at all dosages, whereas a higher dose (100 μM) showed a more significant effect.
Showed a dose-dependent manner in response to ISO treatment.

Western Blot Analysis^[3]

Cell Line:

WT C57BL/6 wild-type mouse lung membranes
Concentration:

0.1; 0.3; 1; 3; 10; 30; 100 μM
Incubation Time:

30 min
Result:

Inhibited Ces1d activity in a does-dependent manner.
Exhibited an IC50 of 2.35 μM.

In Vivo

WWL229 (30 mg/kg; i.p.; single dose) augments LPS-induced acute lung inflammation in a female-specific manner, including enhanced neutrophil infiltration and IL1b mRNA expression in female lungs^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 wild-type mice (adult female and male) with acute lung inflammation model via intraperitoneal LPS challenge^[3]
Dosage:

30 mg/kg
Administration:

i.p.; single dose
Result:

Augmented LPS-induced serum monocyte chemoattractant protein-1 (MCP-1) levels in female mice but not male mice at 6 hours post-LPS challenge.
Enhanced LPS-induced myeloperoxidase (MPO) activity and increased Il1b mRNA levels in female mouse lungs; these effects were not observed in male mouse lungs at 6 hours post-LPS challenge.
Did not alter LPS-induced Il6 or Tnfa mRNA levels in either female or male mouse lungs, nor significantly change other serum cytokine/chemokine levels induced by LPS.
Inhibited lung carboxylesterase (Ces) activity in female mice (but not male mice) at 4 hours post-dosing; inhibited lung Ces activity in both female and male mice to a similar degree by 6 hours post-dosing.
Selectively inhibited lung Ces1d activity in vivo by ~75% at 4 hours, with no inhibition of Ces1c or monoacylglycerol lipase (Magl).

Chemical Information

CAS. Nr. 1338575-28-2
Appearance Liquid (Density: 1.196±0.06 g/cm³)
Molecular Weight 322.36
Formel C₁₆H₂₂N₂O₅
Color Colorless to light yellow
SMILES

O=C(N1CCCCC1CCCOC)OC2=CC=C(C=C2)[N+]([O-])=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (310.21 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1021 mL

15.5106 mL

31.0212 mL

5 mM

0.6204 mL

3.1021 mL

6.2042 mL

10 mM

0.3102 mL

1.5511 mL

3.1021 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Scheaffer HL, et al. Inactivation of CES1 Blocks Prostaglandin D₂ Glyceryl Ester Catabolism in Monocytes/Macrophages and Enhances Its Anti-inflammatory Effects, Whereas the Pro-inflammatory Effects of Prostaglandin E₂ Glyceryl Ester Are Attenuated. ACS Omega. 2020;5(45):29177-29188. Published 2020 Nov 3. [Content Brief]

[2]. Yang L, et al. A Unique Role of Carboxylesterase 3 (Ces3) in β-Adrenergic Signaling-Stimulated Thermogenesis. Diabetes. 2019;68(6):1178-1196. [Content Brief]

[3]. Szafran BN, et al. Carboxylesterase 1d Inactivation Augments Lung Inflammation in Mice. ACS Pharmacol Transl Sci. 2022 Sep 12;5(10):919-931. [Content Brief]

[4]. Borazjani A, et al. Thromboxane A2 synthase is an off target of the CES1 small-molecule inhibitor WWL113. Prostaglandins Other Lipid Mediat. Published online April 3, 2026. [Content Brief]

[5]. Dominguez E, et al. Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. Nat Chem Biol. 2014;10(2):113-121. [Content Brief]

[6]. Taira A, et al. Carboxylesterase 1d-mediated aglycone recognition is crucial for substrate processing and allosteric activation of endo-α-mannosidase in the endoplasmic reticulum. Bioorg Med Chem. 2026;134:118547. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1021 mL	15.5106 mL	31.0212 mL	77.5530 mL
	5 mM	0.6204 mL	3.1021 mL	6.2042 mL	15.5106 mL
	10 mM	0.3102 mL	1.5511 mL	3.1021 mL	7.7553 mL
	15 mM	0.2068 mL	1.0340 mL	2.0681 mL	5.1702 mL
	20 mM	0.1551 mL	0.7755 mL	1.5511 mL	3.8777 mL
	25 mM	0.1241 mL	0.6204 mL	1.2408 mL	3.1021 mL
	30 mM	0.1034 mL	0.5170 mL	1.0340 mL	2.5851 mL
	40 mM	0.0776 mL	0.3878 mL	0.7755 mL	1.9388 mL
	50 mM	0.0620 mL	0.3102 mL	0.6204 mL	1.5511 mL
	60 mM	0.0517 mL	0.2585 mL	0.5170 mL	1.2926 mL
	80 mM	0.0388 mL	0.1939 mL	0.3878 mL	0.9694 mL
	100 mM	0.0310 mL	0.1551 mL	0.3102 mL	0.7755 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

WWL229

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Nuclear Receptor Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Alle Carboxylesterase (CES) Isoform-spezifische Produkte anzeigen

Alle PPAR Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

WWL229 Related Classifications

HY-120602 Related Classifications